StockWatch
·
HomeLiveReports

Amanta Healthcare Ltd Q1 FY27 Results

AMANTAQ1 FY27 Results
Filing
Result:WeakMargin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue68.80 Cr10.6%5.3%
Total Income69.45 Cr11.7%4.8%
Expenditure64.95 Cr8.6%5.9%
PBT4.49 Cr41.0%8.8%
Net Profit3.31 Cr40.1%5.6%
OPM21.13%1.71pp1.68pp
NPM4.77%2.26pp0.52pp
EPS0.8547.2%30.3%
View full financials

Standalone PAT fell 5.6% YoY on only tepid 5.4% revenue growth, with OPM contracting ~170bps (22.8%→21.1%) and NPM slipping to 4.8%, signaling margin pressure rather than core-business strength.

AMANTA HEALTHCARE · Q1 FY27 · THE VERDICT

Revenue on track, profit delayed — overhead absorption masks the Q1 story

Amanta delivered the topline (₹68.8 Cr, +5.4% YoY) but stumbled on the bottom line (₹3.3 Cr, −5.6% YoY), missing prior margin guidance by 200+ basis points. The delay is temporary, not terminal — but it's real.

08 Aug 2026 · 6 min read
Revenue delivered

₹68.8 Cr

+5.4% YoY · on track

PAT delivered

₹3.3 Cr

−5.6% YoY · missed

EBITDA margin

21.8%

vs 24–25% prior guidance

Net margin

4.8%

compressed by overheads, interest, depreciation

Amanta's Q1 result splits into two stories. Revenue grew at the guided pace (+5.4% YoY), and EBITDA margin sat at 21.8% — a hair below 22% prior-year levels. But profits collapsed: PAT fell 5.6% YoY despite revenue growth, net margin compressed to 4.8%, and the company missed the 24–25% EBITDA margin guidance it reiterated on prior calls. The tension is real, but not mysterious. Management's delay of SteriPort Line 3 from Q1 to Q2 forced pre-commissioning overhead absorption into Q1 without offsetting revenue. Polymer costs spiked and were only 67% recovered via price increases. Depreciation and interest rose on new capex. None of this contradicts the long-term thesis — but it means near-term earnings disappointment is not a one-quarter blip.

What changed on this call

Management's claims vs. what holds up

Revenue ₹69 Cr, up 5% YoY

Supported

Delivered ₹68.8 Cr, +5.4% YoY

EBITDA margin approximately 22%

Supported

Delivered 21.8% (₹15 Cr EBITDA on ₹68.8 Cr revenue)

PAT remained healthy despite cost pressures

Overstated

PAT ₹3.3 Cr, −5.6% YoY; NPM 4.8% (constrained)

SteriPort contributes 44% of revenue

Supported

44% of ₹68.8 Cr = ~₹30 Cr; plausible given 90–95% utilization

Capacity expansion delayed to Q2, not withdrawn

Supported

FDA approval Aug 6; commercial production end-August expected. ₹80–85 Cr guidance deferred by one quarter

The real story: SteriPort Line 3 was originally targeted for Q1 commissioning but slipped 4–5 months due to civil construction delays. As a result, manpower hired for the new facility incurred costs in Q1 without contributing revenue. Additionally, polymer raw material spiked 70–80% over ~2 months; Amanta passed through ₹1.50 per unit of the ₹2.25 per unit impact (67% recovery), absorbing the ₹0.75 per unit shortfall. Depreciation and interest expense rose from new capex (solar, SVP prep). The company did not withdraw or materially downgrade FY27–28 guidance — it acknowledged the timing slip and outlined a recovery path: SteriPort Line 3 commissioning late August, baseline revenue ₹370 Cr from existing portfolio, expansion contribution ₹70 Cr over 7 months = ~₹440 Cr FY27 revenue. FY28 peak: ₹425 Cr at 25–26% EBITDA margins once all facilities (SteriPort Line 3, SVP, solar) hit run-rate.

The bull-bear ledger

  • Topline growth on-track; ₹68.8 Cr validates ₹370 Cr baseline assumption

  • SteriPort Line 3 FDA-approved and late-August commissioning on track

  • FY28 peak revenue (₹425 Cr at 25–26% EBITDA) is specific and achievable; strong multi-year visibility

  • Solar capex commissioned; ₹75 lakh per month savings realized (₹9 Cr annually)

  • SVP facility March 2027; 20-product inhalation/ophthalmics pipeline underway; first product Sept 2026

  • PAT down 5.6% YoY despite 5.4% revenue growth; profit margin compressed to 4.8% vs. prior guidance

  • EBITDA margin flat at 21.8% vs. 24–25% prior guidance; recovery deferred to FY28

  • Overhead absorption from pre-commissioning manpower not quantified; Q2+ recovery magnitude unclear

  • Polymer cost pass-through incomplete (67% recovered); future crude-oil spikes pose risk

  • SteriPort Line 3 already delayed 4–5 months; further execution slips would compress FY27 revenue and push margins recovery into late FY27

  • Competitive pressure from MNCs (Otsuka, Fresenius Kabi, B. Braun, Aculife) in SteriPort; Amanta's first-mover moat untested at scale

  • SVP product pipeline aggressive (20 products in 18 months); advanced-market regulatory approvals for inhalation/ophthalmics are slow and uncertain

Risks ranked by severity to a holder

SteriPort Line 3 commissioning delay

High

Already 4–5 month slip from Q1→Q2. FDA inspection scheduled Aug 21 is near-term milestone. Any further delay compresses FY27 guidance (₹70 Cr expansion contribution deferred) and pushes margin recovery into Q4 FY27 at earliest.

Overhead absorption ongoing

High

Pre-commissioning manpower costs absorbed in Q1 without revenue offset. Magnitude not disclosed; unclear how much profit recovery to expect in Q2+ as SteriPort ramps. If overheads are larger or persist longer than expected, margin trajectory slips.

Margin recovery timing

Medium

Management guided 24–25% EBITDA margin for FY27–28 but delivered 21.8% in Q1. Recovery depends on (a) SteriPort Line 3 ramp and overhead absorption, (b) solar ₹9 Cr benefit realization, (c) no further input-cost shocks. Any miss on these variables defers the inflection.

Polymer cost volatility

Medium

Spike described as 2-month anomaly, but crude-oil linkage means future spikes possible. Company recovered only 67% of ₹2.25 per unit impact via price increase; shortfall will spill over 2+ quarters. Another spike would hit margins before price recovery.

SVP regulatory & commercialization

Medium

20-product pipeline in 18 months is ambitious. First inhalation product launch Sept 2026 is unproven at scale. Advanced-market approvals (UK, EU, Australia, Canada) for ophthalmics and inhalation are complex, slow, and carry clinical/regulatory risk.

Competitive intensity in SteriPort

Medium

MNCs (Otsuka, Fresenius Kabi, B. Braun) with deeper R&D, global distribution, and pricing power entering Indian market. Amanta's first-mover moat (ISBM technology) may not hold against aggressive competition. SteriPort realization (net revenue per unit) could face downward pressure.

Leverage and refinancing

Low-Medium

Debt-to-equity 1.06 with added solar capex debt. Interest expense FY27 ₹21 Cr, declining to ₹18–19 Cr FY28. Debt reduction on track (₹30–35 Cr annually) but refinancing risk if rates spike or credit conditions tighten.

How the street sees it

The stock closed at ₹150.01 ahead of the result, +63% off its 52-week low and −8.53% from its all-time high of ₹164. Price momentum is bullish: RSI 60.9 (neutral, not overbought), volume increasing, and the stock trades above all key moving averages (SMA20, SMA50). This positioning suggests the market has factored in some near-term weakness but retains conviction in the long-term story. However, institutional flows tell a different tale: FII ownership declined 25 basis points QoQ (0.85% in Q4 vs. 1.10% in Q3), trimming exposure even as the stock rallied. DII ownership rose 164 basis points QoQ (12.88% vs. 11.24%), indicating domestic institutions are adding. Block/bulk deals over the past 6 months show institutional churn around the ₹156–₹159 price range (near ATH), with sell volume outweighing buy volume by notional value — a sign that tactical profit-taking is occurring at highs. The market's posture is cautiously optimistic: the long-term case (₹425 Cr FY28, 25–26% EBITDA) is accepted, but near-term execution stumbles (margin miss, overhead absorption) are being punished with selective selling at peaks. Holders are not panic-selling; instead, they are waiting for Q2 evidence that margins recover as expected.

Claims to track, Q2 FY27 onwards

What to watch next — 3 concrete things that resolve the debate

  • 1 · SteriPort Line 3 commissioning and early ramp

    FDA inspection scheduled Aug 21, 2026. If cleared, commercial production begins late August. By Q2 FY27 (Oct–Dec), the new line should contribute ~₹30–35 Cr annualized revenue (representing ~1.5–2 months of run-rate). Watch for management's disclosure of actual contribution vs. the ₹70 Cr full-seven-month guidance. Any shortfall signals execution risk; on-track performance validates the ₹440 Cr FY27 revenue and ₹425 Cr FY28 peak.

  • 2 · Q2 EBITDA margin recovery

    EBITDA margin should improve from 21.8% (Q1) toward 23–24% (Q2) as overhead absorption normalizes and SteriPort Line 3 revenue kicks in. Polymer costs have softened since Q1; no further spike expected in Q2. Solar ₹9 Cr annual benefit is now live. If Q2 EBITDA margin stays flat or declines further, it signals either (a) hidden overheads still absorbing, (b) SteriPort ramp slower than expected, or (c) competitive pricing pressure in SteriPort. Watch management's commentary on 'cost normalization' and compare Q2 gross margins (ex overhead) to Q1.

  • 3 · SVP facility progress and first product commercialization

    Inhalation product launch expected Sept 2026 (imminent). SVP facility FAT scheduled USA Nov 2026; deployment Dec 2026; commissioning March 2027. Watch for any delays or product-approval setbacks in advanced markets (UK, EU, Australia, Canada). If on-time, the 20-product pipeline becomes credible and validates management's multi-year growth narrative beyond SteriPort. If delayed, it suggests regulatory approval timelines are longer than guided, reducing conviction in the FY28+ profile.

Amanta is not a distressed story; it is an execution story. The company has built real assets (SteriPort, SVP, solar) and has strong long-term visibility (₹425 Cr FY28 revenue at 25–26% EBITDA). But Q1 revealed that near-term earnings are being sacrificed to fund multi-year capacity buildout. Overhead absorption, partial polymer cost recovery, and rising depreciation/interest have compressed near-term margins and profit. Management has NOT withdrawn guidance — it has deferred it by one quarter. The thesis hinges on the company's ability to (a) commission SteriPort Line 3 on time (late August), (b) absorb new overhead within Q2–Q3, and (c) prove that FY28 margin guidance is achievable without further input-cost shocks or competitive pressure.

For a believer, Q2 is a show-me quarter. The stock is fairly valued at ₹150 IF the long-term case holds and near-term earnings recover as management promises. The risk is that overhead absorption persists, or SteriPort ramp is slower than expected, or competitive MNC pressure forces price concessions. Until proven otherwise, the Hold stance is warranted. The number to track from here is EBITDA margin in Q2 — it should recover 200–250 bps from Q1's 21.8% toward 24% run-rate. If it does, the bear case fades and conviction to Buy strengthens.

Informational and educational content only. Not investment advice.

Amanta Healthcare Ltd (AMANTA) Q1 FY27 Results, Transcript & Analysis — StockWatch